Given the fact that BET inhibitors have clear anticancer activity in a variety of solid tumors and hematologic malignancies [57–59], our findings provide evidence and a rationale for the development of novel therapeutic strategies to improve immune responses in AML based on targeting BRD4. The gene discussed is DNER; the disease is acute myeloid leukemia.